{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:48:05Z","timestamp":1786654085785,"version":"build-2736575974"},"reference-count":205,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100020884","name":"National Agency for Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bcp.2026.118266","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T23:59:50Z","timestamp":1784246390000},"page":"118266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Potential adverse effects of antipsychotics during pregnancy: A narrative review with a focus on metabolic alterations"],"prefix":"10.1016","volume":"252","author":[{"given":"Oriana","family":"Ram\u00edrez-Herrera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"D\u2019Espessailles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Soledad","family":"Burrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8919-833X","authenticated-orcid":false,"given":"Nicolas","family":"Santander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2024","key":"10.1016\/j.bcp.2026.118266_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2023.11.015","article-title":"The schizophrenia syndrome, circa 2024: What we know and how that informs its nature","volume":"264","author":"Tandon","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bcp.2026.118266_b0010","unstructured":"Geneva: World Health Organization, International Classification of Diseases Eleventh Revision (ICD-11), (2022)."},{"key":"10.1016\/j.bcp.2026.118266_b0015","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association, ed., Diagnostic and statistical manual of mental disorders: DSM-5-TR\u2122, Fifth edition, text revision, American Psychiatric Association Publishing, Washington, DC, 2022.","DOI":"10.1176\/appi.books.9780890425787"},{"key":"10.1016\/j.bcp.2026.118266_b0020","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-025-00667-6","article-title":"Schizophrenia","volume":"11","author":"Leucht","year":"2025","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.bcp.2026.118266_b0025","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/s41380-023-01949-9","article-title":"Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment","volume":"28","author":"McCutcheon","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2026.118266_b0030","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/wps.20994","article-title":"Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors","volume":"21","author":"Correll","year":"2022","journal-title":"World Psychiatry"},{"key":"10.1016\/j.bcp.2026.118266_b0035","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: a concise overview of incidence, prevalence, and mortality","volume":"30","author":"McGrath","year":"2008","journal-title":"Epidemiol. Rev."},{"key":"10.1016\/j.bcp.2026.118266_b0040","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/schbul\/sbac041","article-title":"Maintenance Treatment with Antipsychotic Drugs in Schizophrenia: a Cochrane Systematic Review and Meta-analysis","volume":"48","author":"Ceraso","year":"2022","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bcp.2026.118266_b0045","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000477313","article-title":"Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy","volume":"86","author":"Chouinard","year":"2017","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.bcp.2026.118266_b0050","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/schbul\/sbae025","article-title":"Early intervention in Psychosis and Management of First Episode Psychosis in Low- and Lower-Middle-Income Countries: a Systematic Review","volume":"50","author":"Farooq","year":"2024","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bcp.2026.118266_b0055","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/nursrep15010016","article-title":"Intervention Programmes for First-Episode Psychosis: a Scoping Review","volume":"15","author":"Gouveia","year":"2025","journal-title":"Nurs Rep"},{"key":"10.1016\/j.bcp.2026.118266_b0060","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S0140-6736(15)00298-6","article-title":"Evidence for effective interventions to reduce mental-health-related stigma and discrimination","volume":"387","author":"Thornicroft","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.118266_b0065","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1586\/14737175.4.6.S35","article-title":"Maintenance therapy for bipolar disorder: current and future management options","volume":"4","author":"Vieta","year":"2004","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.bcp.2026.118266_b0070","doi-asserted-by":"crossref","unstructured":"L.N. Yatham, S.H. Kennedy, S.V. Parikh, A. Schaffer, D.J. Bond, B.N. Frey, V. Sharma, B.I. Goldstein, S. Rej, S. Beaulieu, M. Alda, G. MacQueen, R.V. Milev, A. Ravindran, C. O\u2019Donovan, D. McIntosh, R.W. Lam, G. Vazquez, F. Kapczinski, R.S. McIntyre, J. Kozicky, S. Kanba, B. Lafer, T. Suppes, J.R. Calabrese, E. Vieta, G. Malhi, R.M. Post, M. Berk, Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder, Bipolar Disord 20 (2018) 97\u2013170. doi: 10.1111\/bdi.12609.","DOI":"10.1111\/bdi.12609"},{"key":"10.1016\/j.bcp.2026.118266_b0075","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/wps.20204","article-title":"Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder","volume":"14","author":"Correll","year":"2015","journal-title":"World Psychiatry"},{"issue":"Suppl 2","key":"10.1016\/j.bcp.2026.118266_b0080","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1055\/s-2004-832669","article-title":"Affective disorders: basic principles regarding clinical course, long-term therapeutic and prophylactic strategies","volume":"37","author":"Marneros","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.bcp.2026.118266_b0085","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00023210-200418040-00005","article-title":"Dopamine partial agonists: a new class of antipsychotic","volume":"18","author":"Lieberman","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bcp.2026.118266_b0090","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2026.118266_b0095","doi-asserted-by":"crossref","first-page":"9532","DOI":"10.3390\/ijms21249532","article-title":"Mechanism of Action of Atypical Antipsychotic Drugs in Mood Disorders","volume":"21","author":"Grinchii","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118266_b0100","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/JCP.0b013e3182214aad","article-title":"Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis","volume":"31","author":"Uchida","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.bcp.2026.118266_b0105","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF02246671","article-title":"Prolactin plasma levels and D2-dopamine receptor occupancy measured with IBZM-SPECT","volume":"124","author":"Schlegel","year":"1996","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2026.118266_b0110","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00004714-199808000-00010","article-title":"Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients","volume":"18","author":"Nordstr\u00f6m","year":"1998","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.bcp.2026.118266_b0115","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.118266_b0120","first-page":"443","article-title":"Comparative Efficacy and Tolerability of 32 Oral Antipsychotics for the Acute Treatment of adults with Multi-Episode Schizophrenia: a Systematic Review and Network Meta-Analysis","volume":"18","author":"Huhn","year":"2020","journal-title":"Focus (am Psychiatr Publ)"},{"key":"10.1016\/j.bcp.2026.118266_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0257129","article-title":"Antipsychotic-induced extrapyramidal side effects: a systematic review and meta-analysis of observational studies","volume":"16","author":"Ali","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2026.118266_b0130","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.3390\/biomedicines10082010","article-title":"Pathophysiological Mechanisms of Antipsychotic-Induced Parkinsonism","volume":"10","author":"Vaiman","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.bcp.2026.118266_b0135","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fnins.2014.00080","article-title":"Basal ganglia vulnerability to oxidative stress","volume":"8","author":"Jensen","year":"2014","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.bcp.2026.118266_b0140","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/BF03033368","article-title":"Antipsychotic-induced oxidative stress in rat brain","volume":"13","author":"Martins","year":"2008","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.bcp.2026.118266_b0145","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0161-813X(03)00114-1","article-title":"The FAD binding sites of human monoamine oxidases a and B","volume":"25","author":"Edmondson","year":"2004","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.bcp.2026.118266_b0150","doi-asserted-by":"crossref","first-page":"273","DOI":"10.4088\/JCP.09r05268yel","article-title":"Antipsychotic medication and oxidative cell stress: a systematic review","volume":"72","author":"Lepping","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bcp.2026.118266_b0155","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","article-title":"Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds","volume":"68","author":"Richelson","year":"2000","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2026.118266_b0160","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2026.118266_b0165","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2026.118266_b0170","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1146\/annurev-med-050911-161504","article-title":"Update on typical and atypical antipsychotic drugs","volume":"64","author":"Meltzer","year":"2013","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.bcp.2026.118266_b0175","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/ddr.21337","article-title":"Improving Current Treatments for Schizophrenia","volume":"77","author":"Maric","year":"2016","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bcp.2026.118266_b0180","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrendo.2015.36","article-title":"New insights in prolactin: pathological implications","volume":"11","author":"Bernard","year":"2015","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bcp.2026.118266_b0185","doi-asserted-by":"crossref","first-page":"T101","DOI":"10.1530\/JOE-15-0213","article-title":"60 years of neuroendocrinology: the hypothalamo-prolactin axis","volume":"226","author":"Grattan","year":"2015","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.bcp.2026.118266_b0190","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/hup.1116","article-title":"Hyperprolactinemia associated with psychotropics\u2013a review","volume":"25","author":"Madhusoodanan","year":"2010","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.bcp.2026.118266_b0195","first-page":"421","article-title":"The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review","volume":"28","author":"Peuskens","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bcp.2026.118266_b0200","first-page":"3","article-title":"Contrasting typical and Atypical Antipsychotic Drugs","volume":"19","author":"Meltzer","year":"2021","journal-title":"Focus (am Psychiatr Publ)"},{"key":"10.1016\/j.bcp.2026.118266_b0205","first-page":"1163","article-title":"Clinical pharmacology of atypical antipsychotics: an update","volume":"13","author":"Mauri","year":"2014","journal-title":"EXCLI J."},{"key":"10.1016\/j.bcp.2026.118266_b0210","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.mp.4002066","article-title":"Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles","volume":"13","author":"Nasrallah","year":"2008","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2026.118266_b0215","first-page":"20","article-title":"Managing anticholinergic side effects, Prim Care Companion","volume":"6","author":"Lieberman","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.bcp.2026.118266_b0220","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.schres.2006.07.011","article-title":"A model of anticholinergic activity of atypical antipsychotic medications","volume":"88","author":"Chew","year":"2006","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bcp.2026.118266_b0225","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02245606","article-title":"Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding","volume":"124","author":"Schotte","year":"1996","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2026.118266_b0230","doi-asserted-by":"crossref","unstructured":"J. Lavalaye, J. Booij, D.H. Linszen, L. Reneman, E.A. van Royen, Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. A[123I]-IDEX SPECT study, Psychopharmacology (Berl) 156 (2001) 53\u201357. doi: 10.1007\/s002130000679.","DOI":"10.1007\/s002130000679"},{"key":"10.1016\/j.bcp.2026.118266_b0235","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bcp.2026.118266_b0240","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.schres.2005.12.855","article-title":"Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication","volume":"83","author":"De Hert","year":"2006","journal-title":"Schizophr. Res."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2026.118266_b0245","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bcp.2026.118266_b0250","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.118266_b0255","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1152\/ajpendo.00164.2018","article-title":"Antipsychotics and glucose metabolism: how brain and body collide","volume":"316","author":"Kowalchuk","year":"2019","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.bcp.2026.118266_b0260","doi-asserted-by":"crossref","DOI":"10.1177\/02698811251400653","article-title":"Effect of cariprazine on metabolic parameters in patients with affective disorders: a systematic review and meta-analysis","author":"Pompili","year":"2026","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.bcp.2026.118266_b0265","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12872-025-05476-z","article-title":"The effect of olanzapine on lipid profiles in humans: a time and dose response meta-analysis of randomized controlled trials","volume":"26","author":"Fang","year":"2026","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.bcp.2026.118266_b0270","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.tem.2014.07.004","article-title":"Molecular pathophysiology of metabolic effects of antipsychotic medications","volume":"25","author":"Ballon","year":"2014","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.bcp.2026.118266_b0275","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.2337\/db13-0430","article-title":"Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease","volume":"62","author":"Teff","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2026.118266_b0280","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1007\/s00125-008-1152-3","article-title":"Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat","volume":"51","author":"Smith","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.bcp.2026.118266_b0285","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.psyneuen.2017.05.005","article-title":"Glucagon receptor knockout mice are protected against acute olanzapine-induced hyperglycemia","volume":"82","author":"Castellani","year":"2017","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.bcp.2026.118266_b0290","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.2337\/diabetes.54.5.1552","article-title":"Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia","volume":"54","author":"Johnson","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.bcp.2026.118266_b0295","first-page":"59","article-title":"Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors, Transl","volume":"11","author":"Aslanoglou","year":"2021","journal-title":"Psychiatry"},{"key":"10.1016\/j.bcp.2026.118266_b0300","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.bcp.2026.118266_b0305","doi-asserted-by":"crossref","first-page":"E624","DOI":"10.1152\/ajpendo.00502.2010","article-title":"Atypical antipsychotic drugs perturb AMPK-dependent regulation of hepatic lipid metabolism","volume":"300","author":"Oh","year":"2011","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.bcp.2026.118266_b0310","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00213-011-2397-y","article-title":"Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat","volume":"219","author":"Jassim","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2026.118266_b0315","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.bbrc.2015.10.045","article-title":"Olanzapine promotes the accumulation of lipid droplets and the expression of multiple perilipins in human adipocytes","volume":"467","author":"Nimura","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2026.118266_b0320","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/sj.mp.4001892","article-title":"Clozapine enhances differentiation of adipocyte progenitor cells","volume":"11","author":"Hemmrich","year":"2006","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2026.118266_b0325","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3892\/etm.2022.11584","article-title":"Olanzapine enhances adipogenesis and suppresses lipolysis in 3T3\u2013L1 adipocytes under low\u2013glucose and weak differentiation\/maturation conditions","volume":"24","author":"Matsuo","year":"2022","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.bcp.2026.118266_b0330","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2174\/1570159X22666240815120547","article-title":"Olanzapine Induces Adipogenesis and Glucose Uptake by Activating Glycolysis and Synergizing with the PI3K-AKT Pathway","volume":"23","author":"Li","year":"2025","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.bcp.2026.118266_b0335","first-page":"145","article-title":"Partial agonists of dopamine receptors: mechanisms and clinical effects of aripiprazole, brexpiprazole and cariprazine, BJPsych","volume":"29","author":"Cookson","year":"2023","journal-title":"Advances"},{"key":"10.1016\/j.bcp.2026.118266_b0340","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/2045125316672136","article-title":"Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole","volume":"7","author":"Frankel","year":"2017","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.bcp.2026.118266_b0345","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","article-title":"The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor","volume":"441","author":"Jordan","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118266_b0350","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1007\/s00213-016-4382-y","article-title":"Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3\/D2 receptor ligand [(11)C]-(+)-PHNO","volume":"233","author":"Girgis","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2026.118266_b0355","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1124\/jpet.119.259879","article-title":"The Role of Dopamine D3 Receptor Partial Agonism in Cariprazine-Induced Neurotransmitter Efflux in Rat Hippocampus and Nucleus Accumbens","volume":"371","author":"Huang","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2026.118266_b0360","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3371\/1935-1232-10.2.109","article-title":"Cariprazine for the Treatment of Schizophrenia: a Review of this Dopamine D3-Preferring D3\/D2 Receptor Partial Agonist","volume":"10","author":"Citrome","year":"2016","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"key":"10.1016\/j.bcp.2026.118266_b0365","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.taap.2018.04.029","article-title":"Dichlorophenyl piperazines, including a recently-approved atypical antipsychotic, are potent inhibitors of DHCR7, the last enzyme in cholesterol biosynthesis","volume":"349","author":"Genaro-Mattos","year":"2018","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118266_b0370","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1038\/s41380-020-0801-x","article-title":"Maternal cariprazine exposure inhibits embryonic and postnatal brain cholesterol biosynthesis","volume":"25","author":"Genaro-Mattos","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2026.118266_b0375","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.schres.2017.02.001","article-title":"Effect of psychotropic drug treatment on sterol metabolism","volume":"187","author":"Korade","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bcp.2026.118266_b0380","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41398-025-03785-7","article-title":"Post-lanosterol inhibition profile based classification of commonly used prescription medications","volume":"16","author":"Tallman","year":"2025","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.bcp.2026.118266_b0385","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1194\/jlr.M079475","article-title":"Vulnerability of DHCR7+\/- mutation carriers to aripiprazole and trazodone exposure","volume":"58","author":"Korade","year":"2017","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bcp.2026.118266_b0390","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41380-019-0368-6","article-title":"Maternal aripiprazole exposure interacts with 7-dehydrocholesterol reductase mutations and alters embryonic neurodevelopment","volume":"24","author":"Genaro-Mattos","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2026.118266_b0395","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.nbd.2011.12.011","article-title":"DHCEO accumulation is a critical mediator of pathophysiology in a Smith-Lemli-Opitz syndrome model","volume":"45","author":"Xu","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bcp.2026.118266_b0400","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.exer.2016.01.016","article-title":"Differential cytotoxic effects of 7-dehydrocholesterol-derived oxysterols on cultured retina-derived cells: Dependence on sterol structure, cell type, and density","volume":"145","author":"Pfeffer","year":"2016","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.bcp.2026.118266_b0405","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jsbmb.2013.11.010","article-title":"7-Dehydrocholesterol metabolites produced by sterol 27-hydroxylase (CYP27A1) modulate liver X receptor activity","volume":"140","author":"Endo-Umeda","year":"2014","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.bcp.2026.118266_b0410","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1006\/mgme.2000.3103","article-title":"Carrier frequency of the common mutation IVS8-1G>C in DHCR7 and estimate of the expected incidence of Smith-Lemli-Opitz syndrome","volume":"72","author":"Battaile","year":"2001","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bcp.2026.118266_b0415","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/cge.12425","article-title":"Determination of the allelic frequency in Smith-Lemli-Opitz syndrome by analysis of massively parallel sequencing data sets","volume":"87","author":"Cross","year":"2015","journal-title":"Clin. Genet."},{"key":"10.1016\/j.bcp.2026.118266_b0420","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1056\/NEJMoa0907328","article-title":"EUROCAT Antiepileptic Study Working Group, Valproic acid monotherapy in pregnancy and major congenital malformations","volume":"362","author":"Jentink","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118266_b0425","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0269881119889296","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology","volume":"34","author":"Barnes","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.bcp.2026.118266_b0430","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"(Systematic Review), the American Psychiatric Association Practice Guideline for the Treatment of patients with Schizophrenia","volume":"177","author":"Keepers","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2026.118266_b0435","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.4088\/JCP.11r07499","article-title":"Pregnancy and bipolar disorder: a systematic review","volume":"73","author":"Sharma","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"#cr-split#-10.1016\/j.bcp.2026.118266_b0440.1","doi-asserted-by":"crossref","unstructured":"A.C. Viguera, T. Whitfield, R.J. Baldessarini, D.J. Newport, Z. Stowe, A. Reminick, A. Zurick, L.S. Cohen, Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation, Am J Psychiatry 164 (2007) 1817-1824","DOI":"10.1176\/appi.ajp.2007.06101639"},{"key":"#cr-split#-10.1016\/j.bcp.2026.118266_b0440.2","doi-asserted-by":"crossref","unstructured":"quiz 1923. doi: 10.1176\/appi.ajp.2007.06101639.","DOI":"10.1176\/appi.ajp.2007.06101639"},{"key":"10.1016\/j.bcp.2026.118266_b0445","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.schres.2020.03.048","article-title":"Antipsychotic drug use in pregnancy: a multinational study from ten countries","volume":"220","author":"Reutfors","year":"2020","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bcp.2026.118266_b0450","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1176\/appi.ajp.2007.06111886","article-title":"Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes","volume":"164","author":"Newport","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2026.118266_b0455","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s10654-024-01156-y","article-title":"Neonatal outcomes after in utero exposure to antipsychotics: a systematic review and meta-analysis","volume":"39","author":"Joseph-Delaffon","year":"2024","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.bcp.2026.118266_b0460","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s00737-025-01651-5","article-title":"Antipsychotic drug use during pregnancy and neonatal outcomes: a systematic review and meta-analysis","volume":"29","author":"Quinn","year":"2026","journal-title":"Arch. Womens Ment. Health"},{"key":"10.1016\/j.bcp.2026.118266_b0465","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.21m14081","article-title":"Pregnancy Outcomes with Exposure to Second-Generation Antipsychotics during the first Trimester","volume":"83","author":"Yakuwa","year":"2022","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bcp.2026.118266_b0470","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jad.2024.12.102","article-title":"Antipsychotic use during pregnancy and outcomes in pregnant individuals and newborns","volume":"373","author":"Cho","year":"2025","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.bcp.2026.118266_b0475","doi-asserted-by":"crossref","unstructured":"Treatment and Management of Mental Health Conditions During Pregnancy and Postpartum: ACOG Clinical Practice Guideline No. 5:, Obstetrics & Gynecology 141 (2023) 1262\u20131288. doi: 10.1097\/AOG.0000000000005202.","DOI":"10.1097\/AOG.0000000000005202"},{"key":"10.1016\/j.bcp.2026.118266_b0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2020.104747","article-title":"Neurobehavioral changes arising from early life dopamine signaling perturbations","volume":"137","author":"Areal","year":"2020","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.bcp.2026.118266_b0485","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.brainres.2007.04.043","article-title":"Dopamine receptor mRNA and protein expression in the mouse corpus striatum and cerebral cortex during pre- and postnatal development","volume":"1156","author":"Araki","year":"2007","journal-title":"Brain Res."},{"key":"10.1016\/j.bcp.2026.118266_b0490","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.neuroscience.2011.10.004","article-title":"Expression and function of dopamine receptors in the developing medial frontal cortex and striatum of the rat","volume":"199","author":"Daws","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.bcp.2026.118266_b0495","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.cell.2016.09.027","article-title":"Molecular Diversity of Midbrain Development in Mouse, Human, and Stem Cells","volume":"167","author":"La Manno","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2026.118266_b0500","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.bbrc.2019.03.105","article-title":"Dopamine stimulates differentiation and migration of cortical interneurons","volume":"512","author":"Ohira","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2026.118266_b0505","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2026.1782731","article-title":"The dopaminergic system in neurodevelopment: preclinical models of neurodevelopmental disorders and susceptibility to neurodegeneration","volume":"20","author":"Santoni","year":"2026","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.bcp.2026.118266_b0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2020.135540","article-title":"The neurodevelopmental role of dopaminergic signaling in neurological disorders","volume":"741","author":"Cai","year":"2021","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bcp.2026.118266_b0515","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1007\/s12035-024-04418-8","article-title":"Dopaminergic Perturbation in the Aetiology of Neurodevelopmental Disorders","volume":"62","author":"Ijomone","year":"2025","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bcp.2026.118266_b0520","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jaac.2025.04.008","article-title":"Systematic Review: Antipsychotic Medication in Pregnancy and Neurodevelopmental Outcomes in Children","volume":"65","author":"Kaplan","year":"2026","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.bcp.2026.118266_b0525","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-026-03610-7","article-title":"Sterol pathway disruption in pregnancy: a link to autism","author":"Peeples","year":"2026","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2026.118266_b0530","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.fertnstert.2007.07.1290","article-title":"Does high body mass index increase the risk of miscarriage after spontaneous and assisted conception?","volume":"90","author":"Metwally","year":"2008","journal-title":"A Meta-Analysis of the Evidence, Fertil Steril"},{"key":"10.1016\/j.bcp.2026.118266_b0535","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1001\/jama.2009.113","article-title":"Maternal overweight and obesity and the risk of congenital anomalies: a systematic review and meta-analysis","volume":"301","author":"Stothard","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2026.118266_b0540","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00404-008-0767-4","article-title":"Maternal obesity is a major risk factor for large-for-gestational-infants in pregnancies complicated by gestational diabetes","volume":"279","author":"Ben-Haroush","year":"2009","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.bcp.2026.118266_b0545","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-067946","article-title":"Gestational diabetes mellitus and adverse pregnancy outcomes: systematic review and meta-analysis","volume":"377","author":"Ye","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.bcp.2026.118266_b0550","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(09)60731-5","article-title":"Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis","volume":"373","author":"Bellamy","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.118266_b0555","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.713418","article-title":"Peripheral Dopamine Directly Acts on Insulin-Sensitive Tissues to Regulate Insulin Signaling and Metabolic Function","volume":"12","author":"Tavares","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118266_b0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.jad.2025.120633","article-title":"Antipsychotic use during pregnancy and risk of gestational diabetes: an updated meta-analysis","volume":"395","author":"Zhang","year":"2026","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.bcp.2026.118266_b0565","article-title":"Effect of antipsychotic consumption during pregnancy on risk of gestational diabetes development: a systematic review and meta-analysis","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.bcp.2026.118266_b0570","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s40263-022-00908-2","article-title":"Antipsychotic Use during Pregnancy and risk for Gestational Diabetes: a National Register-Based Cohort Study in Sweden","volume":"36","author":"Heinonen","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bcp.2026.118266_b0575","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.tem.2006.02.005","article-title":"Focus on prolactin as a metabolic hormone","volume":"17","author":"Ben-Jonathan","year":"2006","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.bcp.2026.118266_b0580","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2265.2010.03814.x","article-title":"Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management","volume":"74","author":"Holt","year":"2011","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"2024","key":"10.1016\/j.bcp.2026.118266_b0585","article-title":"Does hyperprolactinemia treatment affect pregnancy and perinatal outcomes?","volume":"70","author":"Santos","year":"1992","journal-title":"Rev. Assoc. Med. Bras."},{"key":"10.1016\/j.bcp.2026.118266_b0590","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11102-024-01384-1","article-title":"Prolactin-secreting tumors, dopamine agonists and pregnancy: a longitudinal experience of a tertiary neuroendocrine center","volume":"27","author":"Prencipe","year":"2024","journal-title":"Pituitary"},{"key":"10.1016\/j.bcp.2026.118266_b0595","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2265.2010.03808.x","article-title":"Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women","volume":"73","author":"Lebbe","year":"2010","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"10.1016\/j.bcp.2026.118266_b0600","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/09513590.2022.2047173","article-title":"Impact of the prolactin levels in breast cancer: a systematic review and meta-analysis","volume":"38","author":"Aranha","year":"2022","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.bcp.2026.118266_b0605","doi-asserted-by":"crossref","first-page":"25998","DOI":"10.1038\/srep25998","article-title":"Plasma prolactin and breast cancer risk: a meta- analysis","volume":"6","author":"Wang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2026.118266_b0610","article-title":"Antipsychotic-induced hyperprolactinemia: Toxicologic mechanism and the increased breast cancer risk","volume":"14","author":"Bird","year":"2025","journal-title":"Toxicol. Rep."},{"key":"10.1016\/j.bcp.2026.118266_b0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpnec.2025.100313","article-title":"Antipsychotics use increases the risk of breast cancer in Women: Findings from systematic review and meta-analysis of observational studies","volume":"24","author":"Karimi","year":"2025","journal-title":"Compr Psychoneuroendocrinol"},{"key":"10.1016\/j.bcp.2026.118266_b0620","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13058-018-0969-z","article-title":"Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions","volume":"20","author":"Johnston","year":"2018","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bcp.2026.118266_b0625","doi-asserted-by":"crossref","first-page":"17","DOI":"10.21873\/cdp.10174","article-title":"Involvement of the PRL-PAK1 Pathway in Cancer Cell Migration","volume":"3","author":"Carrasco-Ceballos","year":"2023","journal-title":"Cancer Diagn Progn"},{"key":"10.1016\/j.bcp.2026.118266_b0630","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1210\/me.2012-1291","article-title":"Tyrosyl phosphorylated PAK1 regulates breast cancer cell motility in response to prolactin through filamin a","volume":"27","author":"Hammer","year":"2013","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.bcp.2026.118266_b0635","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12860-016-0109-5","article-title":"Prolactin-induced PAK1 tyrosyl phosphorylation promotes FAK dephosphorylation, breast cancer cell motility, invasion and metastasis","volume":"17","author":"Hammer","year":"2016","journal-title":"BMC Cell Biol."},{"key":"10.1016\/j.bcp.2026.118266_b0640","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1021\/acsptsci.1c00012","article-title":"Sterol Biosynthesis Inhibition in Pregnant Women taking Prescription Medications","volume":"4","author":"Genaro-Mattos","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.bcp.2026.118266_b0645","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/JCP.0000000000000171","article-title":"Perinatal use of aripiprazole: plasma levels, placental transfer, and child outcome in 3 new cases","volume":"34","author":"Windhager","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.bcp.2026.118266_b0650","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3109\/00048674.2011.566547","article-title":"Placental transfer of aripiprazole","volume":"45","author":"Nguyen","year":"2011","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.bcp.2026.118266_b0655","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ajmg.1320500407","article-title":"Smith-Lemli-Opitz (RSH) syndrome bibliography: 1964-1993","volume":"50","author":"Opitz","year":"1994","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.bcp.2026.118266_b0660","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/jdb13030022","article-title":"Investigating Psychopharmaceutical Effects on Early Vertebrate Development using a Zebrafish Model System","volume":"13","author":"Zimmerman","year":"2025","journal-title":"J Dev Biol"},{"key":"10.1016\/j.bcp.2026.118266_b0665","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s10735-024-10199-0","article-title":"Prenatal aripiprazole induces alterations of rat placenta: a histological, immunohistochemical and ultrastructural study","volume":"55","author":"Othman","year":"2024","journal-title":"J. Mol. Histol."},{"key":"10.1016\/j.bcp.2026.118266_b0670","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/0269881111424929","article-title":"Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons","volume":"26","author":"Haddad","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.bcp.2026.118266_b0675","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2026.118266_b0680","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1017\/S0033291797005965","article-title":"Neuroleptic drugs in breast-milk: a study of pharmacokinetics and of possible adverse effects in breast-fed infants","volume":"28","author":"Yoshida","year":"1998","journal-title":"Psychol. Med."},{"key":"10.1016\/j.bcp.2026.118266_b0685","first-page":"308","article-title":"Antipsychotic drugs and breastfeeding","volume":"10","author":"Klinger","year":"2013","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"10.1016\/j.bcp.2026.118266_b0690","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4088\/JCP.v66n0307","article-title":"Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study","volume":"66","author":"Diav-Citrin","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bcp.2026.118266_b0695","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1089\/bfm.2019.0093","article-title":"Adverse events in a Breastfed Infant Exposed to Risperidone and Haloperidol","volume":"14","author":"Uguz","year":"2019","journal-title":"Breastfeed. Med."},{"key":"10.1016\/j.bcp.2026.118266_b0700","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/0024-3205(88)90519-X","article-title":"Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites","volume":"43","author":"Hals","year":"1988","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2026.118266_b0705","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/0006-2952(86)90269-8","article-title":"Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding","volume":"35","author":"Dahl","year":"1986","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118266_b0710","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.2174\/1570159X15666170630163616","article-title":"Antipsychotic drugs: from Receptor-binding Profiles to Metabolic Side Effects","volume":"16","author":"Siafis","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.bcp.2026.118266_b0715","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/FTD.0000000000000692","article-title":"Excretion of Antipsychotics into the Amniotic Fluid, Umbilical Cord Blood, and Breast Milk: a Systematic critical Review and combined Analysis","volume":"42","author":"Schoretsanitis","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.bcp.2026.118266_b0720","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1365-2125.1978.tb01639.x","article-title":"Chlorpromazine levels in plasma and milk of nursing mothers","volume":"5","author":"Wiles","year":"1978","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118266_b0725","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1097\/AOG.0000000000000759","article-title":"Obstetric and neonatal outcomes after antipsychotic medication exposure in pregnancy","volume":"125","author":"Coughlin","year":"2015","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.bcp.2026.118266_b0730","first-page":"100","article-title":"Antipsychotic drugs in pregnancy: a review of their maternal and fetal effects, Ther Adv","volume":"5","author":"Galbally","year":"2014","journal-title":"Drug Saf."},{"key":"10.1016\/j.bcp.2026.118266_b0735","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1176\/appi.ajp.2018.17040393","article-title":"Continuation of Atypical Antipsychotic Medication during Early Pregnancy and the risk of Gestational Diabetes","volume":"175","author":"Park","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2026.118266_b0740","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4158\/EP.6.6.425","article-title":"Risperidone-associated hyperprolactinemia","volume":"6","author":"Kearns","year":"2000","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.bcp.2026.118266_b0745","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00004714-200004000-00036","article-title":"Risperidone distribution and excretion into human milk: case report and estimated infant exposure during breast-feeding","volume":"20","author":"Hill","year":"2000","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.bcp.2026.118266_b0750","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1345\/aph.1D326","article-title":"Transfer of risperidone and 9-hydroxyrisperidone into human milk","volume":"38","author":"Ilett","year":"2004","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.bcp.2026.118266_b0755","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/0269881105049044","article-title":"Risperidone and breast-feeding","volume":"19","author":"Aichhorn","year":"2005","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.bcp.2026.118266_b0760","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/JCP.0b013e318206c218","article-title":"A case report of risperidone distribution and excretion into human milk: how to give good advice if you have not enough data available","volume":"31","author":"Weggelaar","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.bcp.2026.118266_b0765","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2165\/00002018-200730030-00006","article-title":"Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes","volume":"30","author":"Coppola","year":"2007","journal-title":"Drug Saf."},{"key":"10.1016\/j.bcp.2026.118266_b0770","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/jamapsychiatry.2016.1520","article-title":"Antipsychotic Use in Pregnancy and the risk for Congenital Malformations","volume":"73","author":"Huybrechts","year":"2016","journal-title":"JAMA Psychiat."},{"key":"10.1016\/j.bcp.2026.118266_b0775","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jamapsychiatry.2022.4109","article-title":"Association of In Utero Antipsychotic Medication Exposure with Risk of Congenital Malformations in Nordic Countries and the US","volume":"80","author":"Huybrechts","year":"2023","journal-title":"JAMA Psychiat."},{"key":"10.1016\/j.bcp.2026.118266_b0780","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","article-title":"Radioreceptor binding profile of the atypical antipsychotic olanzapine","volume":"14","author":"Bymaster","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2026.118266_b0785","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0920-9964(98)00146-7","article-title":"Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro","volume":"37","author":"Bymaster","year":"1999","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bcp.2026.118266_b0790","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0149-2918(00)80086-7","article-title":"The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia","volume":"22","author":"David","year":"2000","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bcp.2026.118266_b0795","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1017\/S1461145702003012","article-title":"Olanzapine excretion in human breast milk: estimation of infant exposure","volume":"5","author":"Croke","year":"2002","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.bcp.2026.118266_b0800","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1176\/appi.ajp.160.8.1428","article-title":"Transfer of olanzapine into breast milk, calculation of infant drug dose, and effect on breast-fed infants","volume":"160","author":"Gardiner","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2026.118266_b0805","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/JCP.0000000000001665","article-title":"Risk of Major Malformations following First-Trimester Exposure to Olanzapine: Preliminary Data from the Massachusetts General Hospital National Pregnancy Registry for Psychiatric Medications","volume":"43","author":"Viguera","year":"2023","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.bcp.2026.118266_b0810","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s002130050492","article-title":"Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia","volume":"135","author":"Gefvert","year":"1998","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2026.118266_b0815","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.schres.2017.01.046","article-title":"Effects of aripiprazole, quetiapine and ziprasidone on plasma prolactin levels in individuals with first episode nonaffective psychosis: Analysis of a randomized open-label 1year study","author":"Crespo-Facorro","year":"2017","journal-title":"Schizophr Res 189"},{"key":"10.1016\/j.bcp.2026.118266_b0820","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1345\/aph.1H555","article-title":"Quetiapine and breast feeding","volume":"41","author":"Rampono","year":"2007","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.bcp.2026.118266_b0825","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/JCP.0000000000000905","article-title":"Quetiapine Excretion into Human Breast Milk","volume":"38","author":"Yazdani-Brojeni","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.bcp.2026.118266_b0830","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1176\/appi.ajp.2018.18010098","article-title":"Risk of Major Malformations in infants following First-Trimester Exposure to Quetiapine","volume":"175","author":"Cohen","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2026.118266_b0835","first-page":"47","article-title":"An overview of the mechanism of action of clozapine","author":"Meltzer","year":"1994","journal-title":"J Clin Psychiatry 55 Suppl B"},{"key":"10.1016\/j.bcp.2026.118266_b0840","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.21r13952","article-title":"Clozapine Treatment during Pregnancy and the Postpartum Period: a Systematic Literature Review","volume":"83","author":"Beex-Oosterhuis","year":"2021","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bcp.2026.118266_b0845","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1176\/ajp.151.6.945","article-title":"Clozapine concentrations in maternal and fetal plasma, amniotic fluid, and breast milk","volume":"151","author":"Barnas","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2026.118266_b0850","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00737-016-0670-0","article-title":"A review of the safety of clozapine during pregnancy and lactation","volume":"20","author":"Mehta","year":"2017","journal-title":"Arch. Womens Ment. Health"},{"key":"10.1016\/j.bcp.2026.118266_b0855","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3389\/fphar.2018.00264","article-title":"Clozapine Use during Pregnancy and Lactation: a Case-Series Report","volume":"9","author":"Imaz","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118266_b0860","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/00023210-199708020-00006","article-title":"Ziprasidone","volume":"8","author":"Davis","year":"1997","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bcp.2026.118266_b0865","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0014-2999(01)01188-8","article-title":"Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile","volume":"425","author":"Schmidt","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118266_b0870","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/bcp.13872","article-title":"Physiologically-based pharmacokinetics of ziprasidone in pregnant women","volume":"85","author":"Biesdorf","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118266_b0875","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1017\/S1461145709009936","article-title":"Low concentration of ziprasidone in human milk: a case report","volume":"12","author":"Schlotterbeck","year":"2009","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.bcp.2026.118266_b0880","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-3565(24)36395-5","article-title":"Neurochemical characteristics of amisulpride, an atypical dopamine D2\/D3 receptor antagonist with both presynaptic and limbic selectivity","volume":"280","author":"Schoemaker","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2026.118266_b0885","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.2165\/00003495-200161140-00014","article-title":"Amisulpride: a review of its use in the management of schizophrenia","volume":"61","author":"Curran","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2026.118266_b0890","first-page":"3","article-title":"The place of amisulpride in the atypical neuroleptic class","volume":"2","author":"Perrault","year":"1996","journal-title":"Encephale 22 Spec No"},{"key":"10.1016\/j.bcp.2026.118266_b0895","first-page":"419","article-title":"Hyperprolactinemia after low dose of amisulpride","volume":"25","author":"Kopecek","year":"2004","journal-title":"Neuro Endocrinol. Lett."},{"key":"10.1016\/j.bcp.2026.118266_b0900","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FTD.0b013e3181f88f70","article-title":"Assessment of infant dose through milk in a lactating woman taking amisulpride and desvenlafaxine for treatment-resistant depression","volume":"32","author":"Ilett","year":"2010","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.bcp.2026.118266_b0905","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/bfm.2010.0016","article-title":"Estimation of rac-amisulpride transfer into milk and of infant dose via milk during its use in a lactating woman with bipolar disorder and schizophrenia","volume":"6","author":"Teoh","year":"2011","journal-title":"Breastfeed. Med."},{"key":"10.1016\/j.bcp.2026.118266_b0910","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/FTD.0000000000000300","article-title":"A Liquid Chromatography-Tandem Mass Spectrometry Method for Quantifying Amisulpride in Human Plasma and Breast Milk, Applied to measuring Drug transfer to a fully Breast-Fed Neonate","volume":"38","author":"O\u02bcHalloran","year":"2016","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.bcp.2026.118266_b0915","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40263-018-0517-5","article-title":"The Safety of Second-Generation Antipsychotics during Pregnancy: a Clinically Focused Review","volume":"32","author":"Damkier","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bcp.2026.118266_b0920","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1176\/appi.ajp.2007.06091479","article-title":"Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study","volume":"164","author":"Mamo","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bcp.2026.118266_b0925","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.neuropharm.2011.08.031","article-title":"Dopamine D2 and serotonin 5-HT1A receptors mediate the actions of aripiprazole in mesocortical and mesoaccumbens transmission","volume":"62","author":"Tanahashi","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2026.118266_b0930","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1517\/13543784.16.6.771","article-title":"Aripiprazole acts as a selective dopamine D2 receptor partial agonist","volume":"16","author":"Wood","year":"2007","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bcp.2026.118266_b0935","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.schres.2008.09.019","article-title":"Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study","volume":"107","author":"Byerly","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bcp.2026.118266_b0940","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/10398562231159510","article-title":"Aripiprazole, brexpiprazole, and cariprazine can affect milk supply: Advice to breastfeeding mothers","volume":"31","author":"Naughton","year":"2023","journal-title":"Australas. Psychiatry"},{"key":"10.1016\/j.bcp.2026.118266_b0945","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/JCP.0000000000001997","article-title":"Lactation-Related Side Effects of Aripiprazole: a Study from Perinatal Psychiatry Services in India","volume":"45","author":"Nanjundaswamy","year":"2025","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.bcp.2026.118266_b0950","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1017\/S1461145707007602","article-title":"Aripiprazole in human milk","volume":"10","author":"Schlotterbeck","year":"2007","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.bcp.2026.118266_b0955","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/JCP.0b013e3181d27c7d","article-title":"Aripiprazole in pregnancy and lactation: a case report","volume":"30","author":"Lutz","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.bcp.2026.118266_b0960","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/JCP.0000000000000079","article-title":"Transfer of aripiprazole to breast milk: a case report","volume":"34","author":"Nordeng","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.bcp.2026.118266_b0965","article-title":"Aripiprazole and lactation failure: the importance of shared decision making","volume":"30","author":"Komaroff","year":"2021","journal-title":"A Case Report, Case Rep Womens Health"},{"key":"10.1016\/j.bcp.2026.118266_b0970","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00737-021-01115-6","article-title":"Reproductive safety of aripiprazole: data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics","volume":"24","author":"Freeman","year":"2021","journal-title":"Arch. Womens Ment. Health"},{"key":"10.1016\/j.bcp.2026.118266_b0975","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/jpet.114.213793","article-title":"Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator","volume":"350","author":"Maeda","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2026.118266_b0980","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3371\/CSRP.MCCI.010316","article-title":"Brexpiprazole for the Treatment of Schizophrenia: a Review of this Novel Serotonin-Dopamine activity Modulator","volume":"9","author":"McEvoy","year":"2016","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"key":"10.1016\/j.bcp.2026.118266_b0985","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/JCP.0000000000000979","article-title":"Effect of Brexpiprazole on Prolactin: an Analysis of Short- and Long-Term Studies in Schizophrenia","volume":"39","author":"Ivkovic","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.bcp.2026.118266_b0990","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/FTD.0000000000001197","article-title":"Pharmacokinetics of Brexpiprazole, Quetiapine, Risperidone, and its active Metabolite Paliperidone in a Postpartum Woman and her Baby","volume":"46","author":"Konishi","year":"2024","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.bcp.2026.118266_b0995","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/15568253251408037","article-title":"Evaluation of the Safety of taking Brexpiprazole during the Lactation Period","volume":"21","author":"Fukuda","year":"2026","journal-title":"Breastfeed. Med."},{"key":"10.1016\/j.bcp.2026.118266_b1000","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.3390\/ph18071010","article-title":"Dopamine Partial Agonists in Pregnancy and Lactation: a Systematic Review","volume":"18","author":"Koukopoulos","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bcp.2026.118266_b1005","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40263-020-00718-4","article-title":"Comparative Tolerability of Dopamine D2\/3 Receptor Partial Agonists for Schizophrenia","volume":"34","author":"Keks","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bcp.2026.118266_b1010","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2147\/NDT.S348143","article-title":"Minimal Effects of Cariprazine on Prolactin Levels in Bipolar Disorder and Schizophrenia","volume":"18","author":"Culpepper","year":"2022","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.bcp.2026.118266_b1015","doi-asserted-by":"crossref","DOI":"10.1097\/JCP.0000000000002174","article-title":"Cariprazine in Human Milk: Cautionary Implications for use during Lactation","author":"Balamurali","year":"2026","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.bcp.2026.118266_b1020","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1421395","article-title":"Cariprazine maintenance treatment during pregnancy \u2013 a case report","volume":"15","author":"Herold","year":"2024","journal-title":"Front. Psychiatry"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226006052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226006052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:17:50Z","timestamp":1786652270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226006052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":205,"alternative-id":["S0006295226006052"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118266","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential adverse effects of antipsychotics during pregnancy: A narrative review with a focus on metabolic alterations","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118266","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118266"}}